## UNCLASSIFIED AD 422020

### DEFENSE DOCUMENTATION CENTER FOR SCIENTIFIC AND TECHNICAL INFORMATION

CAMERON STATION, ALEXANDRIA, VIRGINIA



UNCLASSIFIED

NOTICE: When government or other drawings, specifications or other data are used for any purpose other than in connection with a definitely related government procurement operation, the U. S. Government thereby incurs no responsibility, nor any obligation whatsoever; and the fact that the Government may have formulated, furnished, or in any way supplied the said drawings, specifications, or other data is not to be regarded by implication or otherwise as in any manner licensing the holder or any other person or corporation, or conveying any rights or permission to manufacture, use or sell any patented invention that may in any way be related thereto.

# CATALOGED BY DDC AS AD No. 422020

#### UNCLASSIFIED

Contractor:

BIONETICS RESEARCH LABORATORIES, INC.

Contract No.: DA 18-108-AMC-119(A)

SECOND QUARTERLY PROGRESS REPORT

Covering the Period

22 June 1963 - 22 September 1963

Title: New Methods Development for Irritant Screening

Prepared by

196. TISIA B

E. ROSS HART, Ph.D. Date: 15 October 1963

Copy\_\_\_of\_\_\_copies

UNCLASSIFIED

Bionetics Research Laboratories, Inc. Falls Church, Va. NEW METHODS DEVELOPMENT FOR IRRITANT 1. Irritation, SCREENING - E.Ross Hart Report No. 2, 22 September 63, 5 pp Contract DA 18-108-AMC-119(A) 2. Contract DA 18- 4C08-03-016-07 During second quarter, assessment by current methods was emphasized. Screening current methods was emphasized. Screening completed on approximately 100 compounds. Remainder of 100 compounds. Remainder of 100 compounds will be completed by middle of third quarter. Rat mast cells supply inadequate histamine for test of liberation by irritants.	AD Accession No UNCLASSIFIED Bionetics Research Laboratories, Inc. Falls Church, Va. NEW METHODS DEVELOPMENT FOR IRRITANT 1. Irritation, SCREENING - E.ROSS Hart Report No. 2, 22 September 63, 5 pp Contract DA 18-108-AMC-119(A) 2. Contract DA 18 4C08-03-016-07 During second quarter, assessment by current methods was emphasized. Screening completed on approximately 100 compounds. Remainder of 100 compounds will be completed by middle of third quarter. Rat mast cells supply inadequate histamine for test of liberation by irritants.
ADADAccession NoUNCLASSIFIEDBionetics Research Laboratories, IncUNCLASSIFIED	ADAccession NoUNCLASSIFIEDBiometics Research Laboratories, Inc.Falls Church, Va.UNCLASSIFIEDFalls Church, Va.NEW METHODS DEVELOPMENT FOR IRRITANT1. Irritation,Falls Church, Va.NEW METHODS DEVELOPMENT FOR IRRITANT1. Irritation,SCREENING - E.Ross Hartskin and eyeReport No. 2, 22 September 63, 5 ppcontract DA 18-108-AMC-119(A)2. Contract DA 18Contract DA 18-108-AMC-119(A)2. Contract DA 184C08-03-016-071.008-AMC-119(A)1008-AMC-119(A)000 Unring second quarter, assessment by current methods was emphasized. Screening completed on approximately 100 compounds.1.008-AMC-119(A)Remainder of 100 compounds will be completed by middle of third quarter.Rat mast cells supply inadequate histamine for test of liberation by irritants.UNCLASSIFIED

#### INTRODUCTION

This second quarterly progress report presents a statement of work accomplished during the period from 22 June, 1963 to 22 September, 1963 by the contractor, Bionetics Research Laboratories, Inc., under Contract No. DA 18-108-AMC-119(A).

The report is divided into sections which correspond to the sections of the Statement of Work of the Contract. Thus, Section I (New Methods Development) discusses the progress which has been made in that phase of the work. Section II (Assessment of Irritant Potential) discusses the screening operations under the corresponding phase of that work.

It seems appropriate to point out here that, in accordance with plans developed in conference with the contract project officer, the screening work (Section II) has received the larger share of emphasis during the period herewith reported upon. This was done with the objective of achieving a high degree of efficiency of operation by utilizing a well-trained team full time. That this objective has been achieved will, it is believed, be clear from what follows in Section II. In future period the proportion of emphasis on the two phases of the contract will shift, for the obvious reason that the screening work is nearing completion.

SECTION I - New Methods Development

#### A. Work accomplished

#### Histamine liberation

As mentioned in the first progress report, the decision was made that the investigation of the histamine-liberating characteristics of irritants was to be explored first. It was further decided that the amounts of histamine present in tissues before and after exposure to irritants would be measured by a fluorometric technique, and that the first "tissue" examined would be mast cells isolated from rat peritoneal fluid. At present the fluorometric assay of histamine is proceeding smoothly and presents no difficulties. The method for collection of mast cells originally adopted (Uvnas and Thon, Exptl. Cell Res., 18: 512, 1960 and 23: 45, 1961) presented difficulties in that it provides an inadequate number of mast cells. It has, therefore, been necessary to modify this procedure. That is, instead of withdrawing fluid from the peritoneal cavity of animals previously injected and sacrificed, we are now maintaining a number of animals with regular peritoneal injections and fluid withdrawals in order to produce more massive ascites and consequently larger numbers of mast cells. Preliminary evaluation of mast cells as a source shows that only a limited amount of histamine is released on incubation with irritants. Furthermore, it has thus far shown the differences between irritants to be disappointingly small. At present it is felt that a more adequate survey should be made of the various conditions of incubation of irritants with the cells before this technique is abandoned.

#### Species Survey

A start has been made on the suggested survey of the eyes of a variety of species of animals for use in irritant evaluation. As mentioned in the previous quarterly report, this work has been deliberately deferred in order to allow the project personnel to achieve a high degree of familiarity with the currently used procedures. The survey is now being carried on at a rate that will not unduly interfere with the on going screening operations. The tentative findings, to date are these. After a brief trial, the mouse has been rejected as unsuitable due to his small size. Although some difficulties are encountered in proper restraint of these animals, the principal difficulty is that the mouse eye is so small that there is extreme difficulty in detecting the details of the irritant effect. Similarly a limited number of trials with dogs permits some tentative conclusions. However, these are subject to possible revision when larger numbers of animals and a greater variety of compounds have been tested. Essentially, the same spectrum of signs are produced in the dog as in the rabbit. However, all signs appear to be less intense and to last for a shorter period of time in the dog than in the rabbit. The tentative conclusions are that: (1) the dog is somewhat less sensitive to eye irritation; (2) that the usual dark-colored iris in the dog makes examination somewhat more difficult, and (3) that the combination of blepharospasm and extension of the nictitating membrane which occurs in some dogs in the presence of irritation makes it difficult or occasionally even impossible to observe the iris and cornea.

#### B. Plans for subsequent period:

It has been decided to explore other tissues as sources of histamine in the hope that they may prove more sensitive to histamine liberation by irritants than appears to be the case with rat peritoneal mast cells. The next tissue to be explored is the guinea pig lung. The species survey will, in the very near future, be extended to include cats and certain species of monkeys. With respect to species of monkeys, effort will be made to obtain species with relatively light-colored irises for reasons previously mentioned. At a recent conference with the Contract Project Officer it was decided to initiate exploratory studies of ciliary activity and bronchial muscle (tracheal chain). Steps have been taken to acquire the necessary animals and equipment to follow the procedures described in the proposal.

PART II - Assessment of Irritant Potential

A. Compounds received:

Received 7/24/63

CS	9784	CS	39230	CS	40844
CS	23412	CS	39232	CS	40849
CS	24865	CS	39233	CS	40850
CS	24801	CS	39239	CS	40877
CS	28938	CS	39241	CS	41455
CS	31676	CS	39242	CS	41458
cs	31677	CS	40834	CS	41460
CS	31688	CS	40840	CS	41462
CS	39228	CS	40841	CS	41467
CS	39229	CS	40843	CS	41468

CS 41469 CS 41470 CS 41543 CS 41576 CS 41577 CS 41591 CS 41592 CS 41593	CS 41623 CS 42213 CS 42214 CS 42216 CS 42218 CS 42737 CS 42739 CS 42740	CS 42811 CS 42812 CS 42818 CS 42819 CS 42820 CS 42821 CS 42822 CS 42824
Received 8/22/63		
CS 27644	CS 42056	<b>CS</b> 42990
CS 39651	CS 42057	CS 42997
CS 39654	CS 42064	CS 42998
CS 39666	CS 42066	CS 43000
CS 41722	CS 42069	CS 43001
CS 41723	CS 42224	CS 43054
CS 41724	CS 42354	CS 43157
CS 41725	CS 42355	CS 43166
CS 41726	CS 42356	CS 43168
CS 41727	CS 42982	CS 43169
CS 41763	CS 42983	CS 43175
CS 41864	<b>CS</b> 42984	CS 43176
CS 42039	CS 42985	CS 43178
CS 42049	<b>CS</b> 42986	CS 43179
CS 42054	CS 42987	CS 43180
CS 42055		

#### B. Work completed:

•...

Ę

á v •

Assessment has now been completed on the following compounds which were incomplete at the time of the first report.

CS 15414 CS 15442 CS 18639 CS 20409 CS 23654

Additional compounds on which complete assessment has been accomplished:

CS	9784	CS	36828	CS	39239
EA	118-055-5	CS	36870	CS	39241
EA	119 <b>-400-1</b>	CS	36871	CS	39886
CS	19843	CS	37267	CS	39902
CS	23412	CS	37268	CS	39903
CS	24865	CS	37269	CS	40320
CS	25299	CS	37270	CS	40323
CS	28401	CS	38355	CS	40324
CS	31627	CS	38356	CS	40325
CS	31638	CS	38730	CS	40331
CS	31641	CS	38731	CS	40332
CS	31642	CS	38739	CS	40669
CS	31677	CS	39228	CS	40677
CS	34927	CS	39233	CS	40679
CS	34928				

CS	40683	CS	41470	CS	42213
CS	40686	CS	41577	CS	42216
CS	40781	CS	41591	CS	42739
CS	40785	CS	41593	CS	42740
CS	40800	CS	41623	CS	42818
CS	40801	CS	41722	CS	42819
CS	40804	CS	41725	cs	42820
CS	40805	CS	41726	CS	42822
CS	40806	CS	41763	CS	42985
CS	40840	CS	41864	CS	42986
CS	40844	CS	42049	CS	43001
CS	41455	CS	42055	CS	43166
CS	41467	CS	42056	CS	43168
CS	41468	CS	42057	CS	43176
CS	41469				

Attention is called to an error which has been discovered in the first report. Complete assessment was reported for CS 17593. This should read CS 17953

Compounds on which assessment is incomplete (evaluated for <u>skin</u> irritation only):

CS	31626	CS	42039
CS	39654	CS	42355
CS	40678	CS	42984
CS	40685	CS	42987
CS	40797	CS	42990
CS	40843	CS	42997
CS	41723	CS	43054

Compounds on which assessment is incomplete (evaluated for <u>eye</u> irritation only):

CS	28938	CS	41592
CS	39242	CS	42214
CS	40834	. <b>CS</b>	42218
CS	40841	CS	42747
CS	40849	CS	42811
CS	40850	CS	42821
CS	41460	CS	42824
CS	41462	CS	42998
CS	41543	CS	43000
CS	41576	CS	43169

As provided in the contract, technical reports on this phase of the work have been submitted monthly to the Contract Project Officer.

#### C. Discussion:

By devoting the full time effort of a trained team to this phase of the work the equivalent of complete assessment of approximately 100 compounds has been accomplished (83 complete; 16 eye only; 24 skin only). This fulfills the prediction made in the first report. In fact schedules are now in operation which accomplish complete evaluation of approximately 15 compounds per week.

#### D. Work planned

1.14

On the basis of schedules which have been in operation during the last portions of this report period; we confidently predict complete assessment of the planned 200 compounds by approximately the middle of the third quarter of the contract.

#### SUMMARY

During the second quarter of the contract emphasis has been placed on assessment of compounds by current methods. Histamine liberation from rat mast cells has been found to be small and other tissues are being considered. New directions for methods development are being explored.

Assessment by current methods has been completed on approximately 100 compounds (83 eye and skin; 16 eye only; 24 skin only). Schedules now in operation will permit completion of assessment of the remaining compounds by the middle of the third quarter.